Stocks to consider for the long-term, my man

MYMAN understands you have to be patient when it comes to investing, my man. Below are some stocks that MYMAN is looking at and thinks might turn out to be money-makers down the road. If you are willing to wait six months or more, consider these companies, my man:

Vycor Medical Inc. (OTC:VYCO) - Currently trading at 0.03000

Vycor Medical, Inc. is a developer of neurosurgical medical devices.

Medical International Technology Inc (OTC:MDLH) - Currently trading at 0.0900

Medical International Technology specializes in the research, development, marketing and sale of needle-free jet injector products designed for humans and animals, for single and mass injections. Medical International Technology, Inc. markets several Models of Agro-Jet Needle-Free injectors. The AGRO-JET Model MIT II, MIT III, MIT V, MIT VI, MIT X, MIT XI, MIT XII and MIT XIV. The Company has tree wholly owned subsidiaries, Medical International Technologies Canada, Inc. (MIT Canada), 3567940 Canada inc. and ScanView. ScanView has a portable and battery operated ultrasound diagnostic medical devices, using a variety of probes for pathological and physiological evaluation of organs, such as the heart, kidneys, liver, thyroid, uterus and ovaries.

NeoPharm, Inc. (OTC:NEOL) - Currently trading at 0.230

NeoPharm has five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis (IPF) and asthma.

Inhibitex, Inc. (NASDAQ:INHX) - Currently trading at 0.440

Inhibitex is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent and treat serious infections. The Company focuses in the development of small molecule antiviral compounds, and in particular, therapies to treat shingles (herpes zoster) and chronic hepatitis C infections (HCV). The Company’s anti-infective product candidates include FV-100, HCV Polymerase Inhibitors, HIV Integrase Inhibitors, Aurexis and Staphylococcal Vaccines.

RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) - Currently trading at 0.590

As of December 31, 2008, RegeneRx had formulated three product candidates based on Thymosin beta 4 (Tb4), a 43-amino acid peptide, which are in clinical development. RGN-137 is a topically applied gel for hard-to-heal chronic dermal wounds. RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic wounds. RGN-352 is a parenteral or injectable formulation for systemic delivery of Tb4 to treat cardiovascular disease. The Company is initially targeting its parenteral formulation for the treatment of patients with an acute myocardial infarction or heart attack. RegeneRx has a fourth product candidate, RGN-457, in pre-clinical development. RGN-457 is an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases.